Hikma Pharmaceuticals (LON:HIK) Given New GBX 2,125 Price Target at Jefferies Financial Group

Hikma Pharmaceuticals (LON:HIKGet Rating) had its price target raised by Jefferies Financial Group from GBX 2,080 ($25.87) to GBX 2,125 ($26.43) in a research report issued to clients and investors on Monday, Marketbeat.com reports. The brokerage presently has a “buy” rating on the stock. Jefferies Financial Group’s target price points to a potential upside of 15.33% from the stock’s current price.

Several other analysts have also recently commented on the stock. Barclays reiterated an “equal weight” rating and issued a GBX 1,700 ($21.14) price objective on shares of Hikma Pharmaceuticals in a research note on Wednesday, May 3rd. Citigroup reiterated a “buy” rating and set a GBX 1,920 ($23.88) price target on shares of Hikma Pharmaceuticals in a research report on Tuesday, January 31st. Berenberg Bank upped their price target on Hikma Pharmaceuticals from GBX 1,440 ($17.91) to GBX 1,740 ($21.64) and gave the stock a “hold” rating in a report on Friday, February 24th. Royal Bank of Canada lifted their price objective on Hikma Pharmaceuticals from GBX 1,750 ($21.77) to GBX 1,950 ($24.25) and gave the stock an “outperform” rating in a report on Wednesday, March 1st. Finally, JPMorgan Chase & Co. reissued an “overweight” rating and issued a GBX 2,100 ($26.12) target price on shares of Hikma Pharmaceuticals in a report on Thursday, March 9th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of GBX 1,922.50 ($23.91).

Hikma Pharmaceuticals Price Performance

Hikma Pharmaceuticals stock opened at GBX 1,842.50 ($22.92) on Monday. The company has a market cap of £4.07 billion, a P/E ratio of 2,750.00, a price-to-earnings-growth ratio of 2.38 and a beta of 0.37. Hikma Pharmaceuticals has a one year low of GBX 1,174.50 ($14.61) and a one year high of GBX 1,915.50 ($23.82). The business has a fifty day moving average of GBX 1,775.57 and a two-hundred day moving average of GBX 1,672.39. The company has a debt-to-equity ratio of 59.73, a quick ratio of 1.27 and a current ratio of 1.86.

Hikma Pharmaceuticals Company Profile

(Get Rating)

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded.

Featured Articles

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.